OmniSeq News

Covaris, Inc. and OmniSeq, LLC Today Announced truXTRAC™ FFPE DNA Extraction and Purification Kit as the Method of Choice for Obtaining Clinical-Grade DNA from FFPE Samples for Use with OmniSeq Target℠ Testing

WOBURN, Mass., Sept. 1, 2015 /PRNewswire/ — truXTRAC is a comprehensive novel solution for clinical-grade DNA extraction from Formalin-Fixed, Paraffin-Embedded (FFPE) tissues utilizing Covaris Adaptive Focused Acoustics® (AFA™) technology. The unique focused,...

read more

Follow Us on Twitter

Congrats to Mary Nesline on her paper newly published in @OncotargetJrnl on Tuesday!

https://tinyurl.com/yyrlvd7l

OmniSeq is grateful for the continued support and partnership with @LABCORP . Together, we aim to expand patient access to market leading NGS diagnostics throughout the country. #NGS #TargetedTherapy #Immunotherapy #Diagnostics

https://www.globenewswire.com/news-release/2019/04/23/1807811/0/en/OmniSeq-and-LabCorp-Extend-Exclusive-Distribution-Pact-and-Complete-Follow-On-Investment-Agreement.html

It has been 1 year since the launch of MSI-NGS. OmniSeq allows for MSI testing without the need for matched normal tissue. Let us maximize testing for this important immune oncology biomarker. We identified many MSI-H patients who could not have been tested by PCR! #AACR19

Thank you Wired Magazine and Empire State Development for featuring OmniSeq as a Western New York success story! #ngs #immunotherapy

How One NY Company Is Changing Cancer Treatment

https://www.wired.com/brandlab/2019/03/new-york-state-development-omniseq/

Load More...